{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:00:08Z","timestamp":1789506008039,"version":"build-2803163510"},"update-to":[{"DOI":"10.1371\/journal.pntd.0014152","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000}}],"reference-count":147,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Leprosy is a chronic infectious disease caused by\n                      <jats:italic>Mycobacterium leprae<\/jats:italic>\n                      (\n                      <jats:italic>M. lepra<\/jats:italic>\n                      e\n                      <jats:italic>)<\/jats:italic>\n                      and\n                      <jats:italic>Mycobacterium lepromatosis<\/jats:italic>\n                      (\n                      <jats:italic>M. lepromatosis<\/jats:italic>\n                      ), primarily affecting the skin and peripheral nervous system. Leprosy is complicated by immune-mediated reactions which are risk factors for nerve damage and disability. Systemic corticosteroids are the mainstay of therapy; however, prolonged use in chronic or recurrent reactions carries significant risks but the evidence on the short- and long-term adverse effects of corticosteroids in leprosy is limited. We conducted a systematic review to evaluate corticosteroid-associated adverse effects in leprosy affected individuals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Eight electronic databases were searched (including PubMed, Embase and LILACS) without language or year restriction for studies reporting adverse effects associated with systemic corticosteroid use in individuals with leprosy. Eligible studies included randomised controlled trials, observational studies, case series and case reports. Data variability was assessed using Stata software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Main findings<\/jats:title>\n                    <jats:p>A total of 111 studies were included; of which 22 were randomised controlled trials. Due to heterogeneity, findings were synthesised narratively. The most frequently reported adverse effects were metabolic complications, with approximately one-third of individuals developing corticosteroid-induced lipodystrophy. Infections were the second most common adverse effect (15.5%), followed by gastritis (12.6%). Infections accounted for three-quarters of corticosteroid-associated mortality, predominantly due to tuberculosis, with 88.2% of corticosteroid-associated mortalities occurring in individuals with erythema nodosum leprosum (ENL). There was an association between ENL and the development of cataract and osteoporosis, with 69.7% of cataract cases and 84.4% of osteoporosis cases occurring among individuals with ENL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review illustrates the range and severity of adverse effects affecting individuals with leprosy who received systemic corticosteroids. Although this review is limited by study heterogeneity, publication bias, and the scarcity of long-term data, it highlights the need for corticosteroid stewardship, structured pharmacovigilance and further research for safer therapeutic alternatives to corticosteroids for leprosy reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0014152","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:41:16Z","timestamp":1774546876000},"page":"e0014152","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["A systematic review of adverse effects associated with systemic corticosteroids in the management of leprosy"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3017-7910","authenticated-orcid":true,"given":"Andie I.","family":"Lun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"de Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"12","key":"pntd.0014152.ref001","article-title":"Pathogenesis, clinical considerations, and treatments: a narrative review on leprosy","volume":"15","author":"PH Le","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"pntd.0014152.ref002","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41572-024-00575-1","article-title":"Leprosy","volume":"10","author":"ML Grijsen","year":"2024","journal-title":"Nature Rev Disease Prim"},{"issue":"33","key":"pntd.0014152.ref003","first-page":"365","article-title":"Global leprosy (Hansen disease) update, 2024: beyond zero cases \u2013 what elimination of leprosy really means","volume":"100","author":"World Health Organization","year":"2024","journal-title":"Weekly Epidemiol Rec"},{"issue":"8","key":"pntd.0014152.ref004","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/ddg.13301","article-title":"Leprosy - an overview of clinical features, diagnosis, and treatment","volume":"15","author":"M Fischer","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"pntd.0014152.ref005","first-page":"255","article-title":"Classification of leprosy according to immunity. A five-group system","volume":"34","author":"DS Ridley","year":"1966","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"7","key":"pntd.0014152.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005725","article-title":"Uniform multidrug therapy for leprosy patients in Brazil (U-MDT\/CT-BR): results of an open label, randomized and controlled clinical trial, among multibacillary patients","volume":"11","author":"GO Penna","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0014152.ref007","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamadermatol.2019.1768","article-title":"Risk factors for physical disability in patients with leprosy: a systematic review and meta-analysis","volume":"155","author":"HL de Paula","year":"2019","journal-title":"JAMA Dermatol"},{"key":"pntd.0014152.ref008","doi-asserted-by":"crossref","DOI":"10.3402\/gha.v5i0.18394","article-title":"Disability in people affected by leprosy: the role of impairment, activity, social participation, stigma and discrimination","volume":"5","author":"WH van Brakel","year":"2012","journal-title":"Glob Health Action"},{"key":"pntd.0014152.ref009","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftae013","article-title":"Leprosy reactions: Unraveling immunological mechanisms underlying tissue damage in leprosy patients","volume":"82","author":"H Serrano-Coll","year":"2024","journal-title":"Pathog Dis"},{"issue":"6","key":"pntd.0014152.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010476","article-title":"Understanding leprosy reactions and the impact on the lives of people affected: an exploration in two leprosy endemic countries","volume":"16","author":"AI Putri","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0014152.ref011","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.abd.2021.08.006","article-title":"Leprosy: clinical and immunopathological characteristics","volume":"97","author":"LAR J Froes","year":"2022","journal-title":"An Bras Dermatol"},{"issue":"2","key":"pntd.0014152.ref012","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1489\/1544-581X(2004)072<0125:ECOLRY>2.0.CO;2","article-title":"Epidemiological characteristics of leprosy reactions: 15 years experience from north India","volume":"72","author":"B Kumar","year":"2004","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"1","key":"pntd.0014152.ref013","doi-asserted-by":"crossref","first-page":"14","DOI":"10.47276\/lr.76.1.14","article-title":"The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India","volume":"76","author":"WH van Brakel","year":"2005","journal-title":"Lepr Rev"},{"issue":"5","key":"pntd.0014152.ref014","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1590\/abd1806-4841.20132004","article-title":"Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy","volume":"88","author":"C Nery JA da","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"4","key":"pntd.0014152.ref015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.47276\/lr.74.4.311","article-title":"Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3)","volume":"74","author":"JH Richardus","year":"2003","journal-title":"Lepr Rev"},{"issue":"4","key":"pntd.0014152.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004502","article-title":"A randomized controlled double blind trial of ciclosporin versus prednisolone in the management of leprosy patients with new type 1 reaction, in Ethiopia","volume":"10","author":"SM Lambert","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0014152.ref017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008678","article-title":"Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: a five-year retrospective analysis from a leprosy referral centre in India","volume":"14","author":"B Upputuri","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0014152.ref018","doi-asserted-by":"crossref","first-page":"868","DOI":"10.4269\/ajtmh.2006.74.868","article-title":"Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India","volume":"74","author":"L Pocaterra","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"pntd.0014152.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004065","article-title":"ENLIST 1: an international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum","volume":"9","author":"SL Walker","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0014152.ref020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.47276\/lr.87.2.211","article-title":"Experiences with thalidomide for erythema nodosum leprosum\u2013 a retrospective study","volume":"87","author":"J Darlong","year":"2016","journal-title":"Lepr Rev"},{"issue":"2","key":"pntd.0014152.ref021","doi-asserted-by":"crossref","first-page":"221","DOI":"10.47276\/lr.87.2.221","article-title":"The use of steroids and thalidomide in the management of Erythema Nodosum Leprosum; 17 years at the Hospital for Tropical Diseases, London","volume":"87","author":"LEB Nabarro","year":"2016","journal-title":"Leprosy"},{"issue":"10","key":"pntd.0014152.ref022","article-title":"A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction","volume":"7","author":"CGN Voorend","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0014152.ref023","doi-asserted-by":"crossref","first-page":"355","DOI":"10.47276\/lr.80.4.355","article-title":"Interventions for erythema nodosum leprosum: a cochrane review","volume":"80","author":"NHJ Van Veen","year":"2009","journal-title":"Lepr Rev"},{"issue":"3","key":"pntd.0014152.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002690","article-title":"The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study","volume":"8","author":"SL Walker","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"4787","key":"pntd.0014152.ref025","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/bmj.2.4787.746","article-title":"A.C.T.H. and cortisone in treatment of complications of leprosy","volume":"2","author":"JA Lowe","year":"1952","journal-title":"British Medical Journal"},{"key":"pntd.0014152.ref026","article-title":"Steroids in leprosy type 1 (reversal) reactions: mechanisms of action and effectiveness","author":"DN Lockwood","year":"2000","journal-title":"Lepr Rev"},{"key":"pntd.0014152.ref027","volume-title":"Leprosy\/Hansen Disease: Management of reactions and prevention of disabilities","author":"World Health Organization","year":"2020"},{"issue":"3","key":"pntd.0014152.ref028","doi-asserted-by":"crossref","first-page":"197","DOI":"10.47276\/lr.78.3.197","article-title":"The role of thalidomide in the management of erythema nodosum leprosum","volume":"78","author":"SL Walker","year":"2007","journal-title":"Lepr Rev"},{"issue":"3","key":"pntd.0014152.ref029","doi-asserted-by":"crossref","first-page":"186","DOI":"10.47276\/lr.94.3.186","article-title":"Access to thalidomide","volume":"94","author":"C Ruth Butlin","year":"2023","journal-title":"Leprosy"},{"issue":"4","key":"pntd.0014152.ref030","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae129","article-title":"Unintended consequences: risk of opportunistic infections associated with long-term glucocorticoid therapies in adults","volume":"78","author":"DB Chastain","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pntd.0014152.ref031","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/all.16569","article-title":"Burden of oral corticosteroid use in severe asthma: challenges and opportunities","volume":"80","author":"GW Canonica","year":"2025","journal-title":"Allergy"},{"issue":"1","key":"pntd.0014152.ref032","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-023-01246-6","article-title":"Prevalence of glucocorticoid-induced osteoporosis among rheumatology patients in Africa: a systematic review and meta-analysis","volume":"18","author":"I Hmamouchi","year":"2023","journal-title":"Arch Osteoporos"},{"issue":"10","key":"pntd.0014152.ref033","article-title":"Bisphosphonates for steroid-induced osteoporosis","volume":"10","author":"CS Allen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pntd.0014152.ref034","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15475","article-title":"Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"42","author":"R Golubic","year":"2025","journal-title":"Diabet Med"},{"key":"pntd.0014152.ref035","doi-asserted-by":"crossref","first-page":"1187100","DOI":"10.3389\/fcvm.2023.1187100","article-title":"The role of glucocorticoids in increasing cardiovascular risk","volume":"10","author":"H-W Deng","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"pntd.0014152.ref036","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1210\/clinem\/dgae250","article-title":"European society of endocrinology and endocrine society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency","volume":"109","author":"F Beuschlein","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"pntd.0014152.ref037","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2007.04.018","article-title":"Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study","volume":"57","author":"L Fardet","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"pntd.0014152.ref038","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","article-title":"Glucocorticoid use and abuse in SLE","volume":"51","author":"G Ruiz-Irastorza","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"pntd.0014152.ref039","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"TP van Staa","year":"2002","journal-title":"Osteoporos Int"},{"issue":"4","key":"pntd.0014152.ref040","doi-asserted-by":"crossref","DOI":"10.1186\/ar2764","article-title":"Predictors of major infections in systemic lupus erythematosus","volume":"11","author":"G Ruiz-Irastorza","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"pntd.0014152.ref041","unstructured":"Canada\u2019s Drug Agency. Canada\u2019s drug agency search filters database. 2025. Accessed 2025 July 28. https:\/\/searchfilters.cda-amc.ca\/link\/2"},{"key":"pntd.0014152.ref042","volume-title":"Guidelines for the diagnosis, treatment and prevention of leprosy","author":"World Health Organization","year":"2018"},{"issue":"2","key":"pntd.0014152.ref043","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/bcp.15193","article-title":"Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa","volume":"89","author":"R Kiguba","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"pntd.0014152.ref044","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"issue":"9","key":"pntd.0014152.ref045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"A Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"10","key":"pntd.0014152.ref046","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Z Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"pntd.0014152.ref047","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JJHJ Deeks","year":"2024"},{"key":"pntd.0014152.ref048","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"PT Julian","year":"2024"},{"issue":"4","key":"pntd.0014152.ref049","doi-asserted-by":"crossref","first-page":"319","DOI":"10.47276\/lr.74.4.319","article-title":"Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the \u201cTRIPOD\u201d trials","volume":"74","author":"JH Richardus","year":"2003","journal-title":"Lepr Rev"},{"issue":"3","key":"pntd.0014152.ref050","doi-asserted-by":"crossref","first-page":"236","DOI":"10.47276\/lr.92.3.236","article-title":"Prednisolone adverse events in the treatment and prevention of leprosy neuropathy in two large double blind randomized clinical trials","volume":"92","author":"E Post","year":"2021","journal-title":"Leprosy Rev"},{"issue":"7454","key":"pntd.0014152.ref051","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/bmj.38107.645926.AE","article-title":"Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1)","volume":"328","author":"WCS Smith","year":"2004","journal-title":"BMJ"},{"issue":"4","key":"pntd.0014152.ref052","doi-asserted-by":"crossref","first-page":"300","DOI":"10.47276\/lr.74.4.300","article-title":"The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2)","volume":"74","author":"WH Van Brakel","year":"2003","journal-title":"Lepr Rev"},{"issue":"10","key":"pntd.0014152.ref053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005952","article-title":"Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: a randomized controlled trial","volume":"11","author":"I Wagenaar","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0014152.ref054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001041","article-title":"A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and\/or nerve function impairment","volume":"5","author":"SL Walker","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0014152.ref055","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1590\/S0004-282X2008000600016","article-title":"A randomized clinical trial of oral steroids for ulnar neuropathy in type 1 and type 2 leprosy reactions","volume":"66","author":"JA Garbino","year":"2008","journal-title":"Arq Neuropsiquiatr"},{"issue":"10","key":"pntd.0014152.ref056","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.trstmh.2003.12.013","article-title":"Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal","volume":"98","author":"SNS Marlowe","year":"2004","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"pntd.0014152.ref057","article-title":"AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings","volume":"11","author":"DNJ Lockwood","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0014152.ref058","first-page":"233","article-title":"Pulsed corticosteroid therapy in patients with chronic recurrent ENL: a pilot study","volume":"74","author":"A Girdhar","year":"2002","journal-title":"Indian J Lepr"},{"issue":"1","key":"pntd.0014152.ref059","first-page":"448","article-title":"Evaluation of methotrexate and sodium stibogluconate in the patients of type two lepra reactions","volume":"16","author":"P Sakhare","year":"2024","journal-title":"Inter J Pharm Clin Res"},{"issue":"5690","key":"pntd.0014152.ref060","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/bmj.1.5690.198","article-title":"Double-blind controlled clinical trial of clofazimine in reactive phases of lepromatous leprosy","volume":"1","author":"AB Karat","year":"1970","journal-title":"Br Med J"},{"issue":"1","key":"pntd.0014152.ref061","first-page":"66","article-title":"Indomethacin in the treatment of erythema nodosum leprosum, in comparison with prednisolone","volume":"10","author":"TH Ing","year":"1969","journal-title":"Singapore Med J"},{"issue":"3","key":"pntd.0014152.ref062","first-page":"153","article-title":"Indomethacin in the management of erythema nodosum leprosum--a double-blind controlled trial","volume":"40","author":"AB Karat","year":"1969","journal-title":"Lepr Rev"},{"issue":"1","key":"pntd.0014152.ref063","first-page":"29","article-title":"Comparative efficacy of four treatment regimens in Type 2 leprosy reactions (Prednisolone alone, Thalidomide alone, Prednisolone plus Thalidomide and Prednisolone plus Clofazimine)","volume":"88","author":"HK Kar","year":"2016","journal-title":"Indian J Lepr"},{"issue":"3","key":"pntd.0014152.ref064","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1440-0960.2009.00534.x","article-title":"Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study","volume":"50","author":"I Kaur","year":"2009","journal-title":"Australas J Dermatol"},{"issue":"2","key":"pntd.0014152.ref065","first-page":"128","article-title":"Clinical evaluation studies in lepromatous leprosy. Sixth series: effect (on lepra reaction) of supplementing DDS with dexamethasone, methandrostenolone, or mefenamic acid","volume":"35","author":"JA Doull","year":"1967","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"2","key":"pntd.0014152.ref066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004149","article-title":"Comparison of efficacy and safety of ciclosporin to prednisolone in the treatment of erythema nodosum leprosum: two randomised, double blind, controlled pilot studies in ethiopia","volume":"10","author":"SM Lambert","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0014152.ref067","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15125","article-title":"Comparison of the efficacy and safety of minocycline and clofazimine in chronic and recurrent erythema nodosum leprosum-A randomized clinical trial","volume":"34","author":"V Hanumanthu","year":"2021","journal-title":"Dermatol Ther"},{"issue":"11","key":"pntd.0014152.ref068","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/ijd.12793","article-title":"Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: a double-blind, randomized, controlled study","volume":"54","author":"K Roy","year":"2015","journal-title":"Int J Dermatol"},{"key":"pntd.0014152.ref069","unstructured":"Martinus D, Menaldi SL, Rihatmadja R. Comparison between oral pentoxifylline corticosteroid and oral corticosteroid alone for severe erythema nodosum leprosum: a randomized, double-blind controlled trial. In: Journal of the Dermatology Nurses\u2019 Association Conference, Milan, Italy, 2020."},{"issue":"3","key":"pntd.0014152.ref070","first-page":"489","article-title":"Corticosteroids and lepromin sensitivity","volume":"54","author":"SK Kundu","year":"1982","journal-title":"Lepr India"},{"issue":"3","key":"pntd.0014152.ref071","first-page":"337","article-title":"Steroid therapy for paralytic deformities in leprosy","volume":"65","author":"DS Sugumaran","year":"1997","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"1","key":"pntd.0014152.ref072","first-page":"10","article-title":"Leprosy reactions--complications of steroid therapy","volume":"66","author":"DS Sugumaran","year":"1998","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"3","key":"pntd.0014152.ref073","first-page":"125","article-title":"A study of steroid-induced diabetes mellitus in leprosy","volume":"81","author":"R Papang","year":"2009","journal-title":"Indian J Lepr"},{"issue":"3","key":"pntd.0014152.ref074","first-page":"412","article-title":"Steroid therapy in recent \u201cquiet nerve paralysis\u201d in leprosy. Report of a study of twenty-five patients","volume":"54","author":"H Srinivasan","year":"1982","journal-title":"Lepr India"},{"issue":"1","key":"pntd.0014152.ref075","first-page":"164","article-title":"Borderline reactions treated with clofazimine and corticosteroids","volume":"57","author":"T Thirugnanam","year":"1985","journal-title":"Indian J Lepr"},{"issue":"3","key":"pntd.0014152.ref076","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5935\/0305-7518.20000032","article-title":"The ALERT MDT Field Evaluation Study (AMFES): a descriptive study of leprosy in Ethiopia. Patients, methods and baseline characteristics","volume":"71","author":"P Saunderson","year":"2000","journal-title":"Leprosy Review"},{"issue":"2","key":"pntd.0014152.ref077","first-page":"115","article-title":"Thalidomide in severe erythema nodosum leprosum (Enl)-our experience in chronic, recurrent and steroid-dependant cases","volume":"93","author":"P Singla","year":"2021","journal-title":"Indian J Leprosy"},{"issue":"1","key":"pntd.0014152.ref078","first-page":"105","article-title":"Using methotrexate to treat patients with ENL unresponsive to steroids and clofazimine: a report on 9 patients","volume":"84","author":"D Hossain","year":"2013","journal-title":"Lepr Rev"},{"issue":"12","key":"pntd.0014152.ref079","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007035","article-title":"The effects of prednisolone treatment on serological responses and lipid profiles in Ethiopian leprosy patients with Erythema Nodosum Leprosum reactions","volume":"12","author":"E Negera","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014152.ref080","first-page":"243","article-title":"Managing a case of steroid dependant erythema necroticans in a severely immune-compromised patient: Case report","volume":"96","author":"S Mishra","year":"2024","journal-title":"Indian J Leprosy"},{"key":"pntd.0014152.ref081","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.2147\/IDR.S217181","article-title":"Leprosy reactions in childhood: a prospective cohort study in the brazilian amazon","volume":"12","author":"SS Bandeira","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"1","key":"pntd.0014152.ref082","doi-asserted-by":"crossref","first-page":"41","DOI":"10.47276\/lr.81.1.41","article-title":"The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT","volume":"81","author":"VP Shetty","year":"2010","journal-title":"Lepr Rev"},{"issue":"2","key":"pntd.0014152.ref083","first-page":"127","article-title":"The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen","volume":"56","author":"KU Kiran","year":"1985","journal-title":"Lepr Rev"},{"issue":"3","key":"pntd.0014152.ref084","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/ijp.ijp_946_21","article-title":"Thalidomide and steroid in the management of erythema nodosum leprosum","volume":"54","author":"SR P K Mishra","year":"2022","journal-title":"Indian J Pharmacol"},{"key":"pntd.0014152.ref085","doi-asserted-by":"crossref","first-page":"20503121221089448","DOI":"10.1177\/20503121221089448","article-title":"Analysis of therapeutic effectiveness and adverse effects of long-term corticosteroids among leprosy patients with reactions: a retrospective cohort study","volume":"10","author":"JN Siagian","year":"2022","journal-title":"SAGE Open Med"},{"issue":"1","key":"pntd.0014152.ref086","doi-asserted-by":"crossref","first-page":"68","DOI":"10.47276\/lr.90.1.68","article-title":"Retrospective study of the morbidity associated with erythema nodosum leprosum in Brazilian leprosy patients","volume":"90","author":"D Neves","year":"2019","journal-title":"Leprosy Review"},{"issue":"1","key":"pntd.0014152.ref087","article-title":"Oral corticosteroid therapy in leprosy\u2019s new patients with type 2 reaction","volume":"27","author":"I Listiyawati","year":"2015","journal-title":"Period Dermatol Venereol"},{"issue":"4","key":"pntd.0014152.ref088","doi-asserted-by":"crossref","first-page":"398","DOI":"10.47276\/lr.75.4.398","article-title":"Death caused by strongyloides hyperinfection in a leprosy patient on treatment for a type II leprosy reaction","volume":"75","author":"B Leang","year":"2004","journal-title":"Lepr Rev"},{"issue":"4","key":"pntd.0014152.ref089","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4103\/0377-4929.168871","article-title":"A 36-year-old man with vomiting, pain abdomen, significant weight loss, hyponatremia, and hypoglycemia","volume":"58","author":"D Mutreja","year":"2015","journal-title":"Indian J Pathol Microbiol"},{"issue":"2","key":"pntd.0014152.ref090","first-page":"145","article-title":"A fatal case of erythema necroticans","volume":"74","author":"SV Davis","year":"2002","journal-title":"Indian J Lepr"},{"issue":"5","key":"pntd.0014152.ref091","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4103\/ijp.IJP_764_16","article-title":"Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus","volume":"49","author":"S Pai","year":"2017","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"pntd.0014152.ref092","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4269\/ajtmh.16-0118","article-title":"Therapeutic Dilemma of Refractory Erythema Nodosum Leprosum","volume":"96","author":"J Zhu","year":"2017","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"pntd.0014152.ref093","first-page":"289","article-title":"Diabetic ketoacidosis following steroid therapy in a rural leprosy hospital","volume":"63","author":"VK Edward","year":"1995","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"1","key":"pntd.0014152.ref094","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s13256-022-03673-4","article-title":"Strongyloidiasis infection in a borderline lepromatous leprosy patient with adrenocorticoid insufficiency undergoing corticosteroid treatment: a case report","volume":"16","author":"R Morel","year":"2022","journal-title":"J Med Case Rep"},{"issue":"4","key":"pntd.0014152.ref095","first-page":"237","article-title":"Hypothalamo-pituitary axis suppression: a risk factor for late onset bullous ENL?","volume":"88","author":"R Monteiro","year":"2016","journal-title":"Indian J Leprosy"},{"issue":"4","key":"pntd.0014152.ref096","doi-asserted-by":"crossref","first-page":"536","DOI":"10.47276\/lr.87.4.536","article-title":"Strongyloides hyper infection in a steroid dependent leprosy patient","volume":"87","author":"J Darlong","year":"2016","journal-title":"Lepr Rev"},{"issue":"3","key":"pntd.0014152.ref097","first-page":"223","article-title":"A case of subcutaneous phaeohyphomycosis associated with leprosy","volume":"17","author":"MMR Teixeira","year":"2017","journal-title":"Infect Disord Drug Targets"},{"key":"pntd.0014152.ref098","doi-asserted-by":"crossref","first-page":"108741","DOI":"10.1016\/j.ijscr.2023.108741","article-title":"Role of cytopathology in diagnosing phaeohyphomycosis masquerading as nerve abscess in a lepromatous leprosy patient: a case report","volume":"110","author":"SK Yadav","year":"2023","journal-title":"Int J Surg Case Rep"},{"issue":"2","key":"pntd.0014152.ref099","first-page":"104","article-title":"Nocardia farcinica pleuritis in a lepromatous patient with severe necrotizing reaction: an unusual presentation","volume":"69","author":"S Arunthathi","year":"2001","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"pntd.0014152.ref100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/1471-2334-13-162","article-title":"Left thigh phlegmon caused by Nocardia farcinica identified by 16S rRNA sequencing in a patient with leprosy: a case report","volume":"13","author":"P De Nardo","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"7","key":"pntd.0014152.ref101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D36PX3R9ZK","article-title":"Nocardia nova mycetoma over forehead in a lepromatous leprosy patient","volume":"18","author":"M Dhingra","year":"2012","journal-title":"Dermatol Online J"},{"issue":"5","key":"pntd.0014152.ref102","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/ijd.13961","article-title":"Systemic nocardiosis in a lepromatous leprosy patient with type 2 reaction","volume":"57","author":"M Pretty","year":"2018","journal-title":"Int J Dermatol"},{"issue":"4","key":"pntd.0014152.ref103","doi-asserted-by":"crossref","first-page":"429","DOI":"10.47276\/lr.79.4.429","article-title":"Immune reconstitution inflammatory syndrome or upgrading type 1 reaction? Report of two AIDS patients presenting a shifting from borderline lepromatous leprosy to borderline tuberculoid leprosy","volume":"79","author":"C Talhari","year":"2008","journal-title":"Lepr Rev"},{"issue":"1","key":"pntd.0014152.ref104","doi-asserted-by":"crossref","first-page":"58","DOI":"10.47276\/lr.85.1.58","article-title":"Recurrence of strongyloides stercoralis infection in a patient with Hansen\u2019s disease: a case report","volume":"85","author":"JN De Souza","year":"2014","journal-title":"Lepr Rev"},{"issue":"11","key":"pntd.0014152.ref105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037700","article-title":"Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial","volume":"10","author":"B de Barros","year":"2020","journal-title":"BMJ Open"},{"issue":"2","key":"pntd.0014152.ref106","doi-asserted-by":"crossref","first-page":"181","DOI":"10.47276\/lr.75.2.181","article-title":"A case of post-partum borderline tuberculoid leprosy complicated by a median nerve abscess, peptic ulceration and rifampicin-induced haemolytic renal failure","volume":"75","author":"S Dawe","year":"2004","journal-title":"Lepr Rev"},{"issue":"1","key":"pntd.0014152.ref107","first-page":"115","article-title":"Ocular leprosy: do steroids complicate matters?","volume":"63","author":"E Daniel","year":"1995","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"3","key":"pntd.0014152.ref108","first-page":"165","article-title":"Ileofemoral Deep Vein Thrombosis (DVT) in steroid treated lepra type 2 reaction patient","volume":"87","author":"P Thangaraju","year":"2015","journal-title":"Indian J Lepr"},{"issue":"1","key":"pntd.0014152.ref109","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1590\/0037-8682-0216-2017","article-title":"Anti-phospholipid syndrome in seven leprosy patients with thrombotic events on corticosteroid and\/or thalidomide regimen: insights on genetic and laboratory profiles","volume":"51","author":"S Vernal","year":"2018","journal-title":"Rev Soc Bras Med Trop"},{"issue":"4","key":"pntd.0014152.ref110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0090-3019(82)90127-6","article-title":"Acute collapse of thoracic vertebral bodies after long-term steroid treatment in leprosy","volume":"17","author":"V Lombardi","year":"1982","journal-title":"Surg Neurol"},{"issue":"4","key":"pntd.0014152.ref111","first-page":"708","article-title":"The danger of steroid therapy in leprosy","volume":"41","author":"U Nguyen V a n","year":"1973","journal-title":"International Journal of Leprosy"},{"issue":"2","key":"pntd.0014152.ref112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292507","article-title":"Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: a multicenter, retrospective cohort study","volume":"19","author":"K Miyake","year":"2024","journal-title":"PLoS One"},{"issue":"6","key":"pntd.0014152.ref113","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"GE Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"pntd.0014152.ref114","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/archdischild-2015-309522","article-title":"Systematic review of the toxicity of short-course oral corticosteroids in children","volume":"101","author":"F Aljebab","year":"2016","journal-title":"Arch Dis Child"},{"issue":"1","key":"pntd.0014152.ref115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1186\/s12887-025-06024-6","article-title":"Factors associated with mortality in immunocompromised children with varicella","volume":"25","author":"AK Putri","year":"2025","journal-title":"BMC Pediatr"},{"issue":"8","key":"pntd.0014152.ref116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003018","article-title":"Strongyloidiasis--an insight into its global prevalence and management","volume":"8","author":"S Puthiyakunnon","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0014152.ref117","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.cmi.2021.07.016","article-title":"Clinical and laboratory features of Strongyloides stercoralis infection at diagnosis and after treatment: a systematic review and meta-analysis","volume":"27","author":"D Buonfrate","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"pntd.0014152.ref118","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ebiom.2017.08.026","article-title":"Opening a can of worms: leprosy reactions and complicit soil-transmitted helminths","volume":"23","author":"DA Hagge","year":"2017","journal-title":"EBioMedicine"},{"issue":"1","key":"pntd.0014152.ref119","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jinf.2006.01.016","article-title":"Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review","volume":"54","author":"L Fardet","year":"2007","journal-title":"J Infect"},{"key":"pntd.0014152.ref120","volume-title":"WHO guideline on preventative chemotherapy for public health control of strongyloidiasis","author":"World Health Organization","year":"2024"},{"key":"pntd.0014152.ref121","volume-title":"National strategic plan and roadmap for leprosy 2023-2027","author":"National Leprosy Eradication Programme","year":"2023"},{"key":"pntd.0014152.ref122","unstructured":"Society for Endocrinology. Adrenal insufficiency and adrenal crisis-who is at risk and how should they be managed safely. 2021. Accessed 2025 August 20. https:\/\/www.endocrinology.org\/media\/4091\/spssfe_supporting_sec_-final_10032021-1.pdf"},{"issue":"5","key":"pntd.0014152.ref123","article-title":"Society for endocrinology endocrine emergency guidance: emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients","volume":"5","author":"Arlt W, Society for Endocrinology Clinical Committee","year":"2016","journal-title":"Endocr Connect"},{"key":"pntd.0014152.ref124","unstructured":"National Institute for Health and Care Excellence. Scenario: corticosteroids. 2025. Accessed 2025 September 14. https:\/\/cks.nice.org.uk\/topics\/corticosteroids-oral\/management\/corticosteroids\/#monitoring"},{"key":"pntd.0014152.ref125","volume-title":"Leprosy Care","author":"The Leprosy Mission Trust India","year":"2020"},{"issue":"1","key":"pntd.0014152.ref126","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"D Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"pntd.0014152.ref127","volume-title":"NHDP guide to the management of Hansen\u2019s disease","author":"Health Resources and Services Administration","year":"2025"},{"key":"pntd.0014152.ref128","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2023"},{"key":"pntd.0014152.ref129","volume-title":"WHO consolidated guidelines on tuberculosis. Module 2: screening \u2013 systematic screening for tuberculosis disease","author":"World Health Organization","year":"2021"},{"issue":"1","key":"pntd.0014152.ref130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"V Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"pntd.0014152.ref131","volume-title":"Protocolo cl\u00ednico e diretrizes terap\u00eauticas da hansen\u00edase Brasil","author":"MSSV Sa\u00fade","year":"2022"},{"key":"pntd.0014152.ref132","volume-title":"Management of strongyloidiasis","year":"2018"},{"issue":"1","key":"pntd.0014152.ref133","article-title":"Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection","volume":"2016","author":"C Henriquez-Camacho","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"pntd.0014152.ref134","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","article-title":"EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"66","author":"JN Hoes","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pntd.0014152.ref135","first-page":"111","article-title":"Good clinical practice recommendations for proton pump inhibitor prescription and deprescription. A review by experts from the AMG","volume":"90","author":"LR Valdovinos-Garc\u00eda","year":"2025","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"issue":"12","key":"pntd.0014152.ref136","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/acr.25240","article-title":"2022 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"MB Humphrey","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"pntd.0014152.ref137","volume-title":"User\u2019s manual of systemic and topical steroids","author":"V Indian Association of Dermatologists","year":"2020"},{"issue":"3","key":"pntd.0014152.ref138","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"SV Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"pntd.0014152.ref139","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70177","article-title":"Prevention and treatment of venous thromboembolism in patients with multiple myeloma: clinical practice guidelines on behalf of the European Myeloma Network","volume":"9","author":"G Gerotziafas","year":"2025","journal-title":"Hemasphere"},{"issue":"10","key":"pntd.0014152.ref140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240971","article-title":"Prevalence of metabolic syndrome among adult population in India: a systematic review and meta-analysis","volume":"15","author":"Y Krishnamoorthy","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"pntd.0014152.ref141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167320","article-title":"Metabolic syndrome and associated factors in adults of the amazon region","volume":"11","author":"SL Fran\u00e7a","year":"2016","journal-title":"PLoS One"},{"key":"pntd.0014152.ref142","doi-asserted-by":"crossref","first-page":"947659","DOI":"10.3389\/fmed.2022.947659","article-title":"Drugs associated with cataract formation represent an unmet need in cataract research","volume":"9","author":"J Carlson","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"pntd.0014152.ref143","first-page":"139","article-title":"Cataract: the main cause of blindness in leprosy","volume":"72","author":"M Hogeweg","year":"2001","journal-title":"Lepr Rev"},{"key":"pntd.0014152.ref144","first-page":"100938","article-title":"Trends and disparities in non-communicable diseases in the Western Pacific region","volume":"43","author":"W Peng","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"pntd.0014152.ref145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003431","article-title":"Household costs of leprosy reactions (ENL) in rural India","volume":"9","author":"DJ Chandler","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0014152.ref146","doi-asserted-by":"crossref","first-page":"2501163","DOI":"10.1080\/17441692.2025.2501163","article-title":"Development, validation and reliability of knowledge, attitudes and practice questionnaire for people affected by leprosy reactions","volume":"20","author":"AT Maulana","year":"2025","journal-title":"Glob Public Health"},{"key":"pntd.0014152.ref147","doi-asserted-by":"crossref","DOI":"10.2471\/B09421","volume-title":"Regulation and prequalification","author":"World Health Organization","year":"2025"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0014152","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:48:40Z","timestamp":1774979320000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014152"}},"subtitle":[],"editor":[{"given":"Anil","family":"Fastenau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":147,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0014152","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}